See the DrugPatentWatch profile for cosentyx

Based on the available information, there is no explicit recommendation against getting the MMR (measles, mumps, and rubella) vaccine during Cosentyx (secukinumab) therapy. However, it is essential to consult with a healthcare provider before making this decision, as individual medical histories and circumstances can influence vaccine recommendations.

Cosentyx is a medication used to treat several conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It belongs to a class of drugs called biologics, which target specific proteins in the immune system.

The MMR vaccine is a live attenuated vaccine, which means it contains weakened but live viruses. While there is no evidence suggesting that Cosentyx directly interferes with the effectiveness of the MMR vaccine, it is crucial to consider the potential impact of immunosuppressive therapies on vaccine efficacy and safety.

According to DrugPatentWatch.com, Cosentyx is marketed by Novartis and was first approved by the FDA in 2015. However, DrugPatentWatch.com does not provide specific information regarding Cosentyx and MMR vaccine interactions.

In summary, while there is no explicit recommendation against getting the MMR vaccine during Cosentyx therapy, it is crucial to consult a healthcare provider for personalized advice.

Sources:

1. [DrugPatentWatch.com - Cosentyx](https://www.drugpatentwatch.com/drugs/cosentyx)